Results 51 to 60 of about 14,264 (186)

Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland

Diabetic Medicine, EarlyView.
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies   +14 more
wiley   +1 more source

A novel deep intronic EIF2AK3 variant disrupts splicing and causes Wolcott–Rallison syndrome

Diabetic Medicine, EarlyView.
Abstract Aim Deep intronic variants can disrupt splicing and cause monogenic disease but are missed by routine genetic testing. This study assessed the contribution of deep intronic variants to Wolcott–Rallison syndrome (WRS), a recessive disorder characterized by early‐onset diabetes and progressive multisystem disease caused by loss‐of‐function ...
Alaa Al Assi, Georgia Bonfield, James Russ‐Silsby, Suhel Ahmed, Thomas W. Laver, Kadri Karaer, Bayram Özhan, Ayca Altincik, Kashyap A. Patel, Jayne A. L. Houghton, Sarah E. Flanagan, Matthew B. Johnson, Elisa De Franco   +12 more
wiley   +1 more source

Evaluation of Early Insulin Glargine Administration in the Treatment of Pediatric Diabetic Ketoacidosis

, 2023
OBJECTIVE: In the management of diabetic ketoacidosis (DKA), the standard of care is to administer insulin glargine after ketoacidosis has resolved and the patient is transitioning from intravenous (IV) insulin to subcutaneous insulin; however, there is ...
Welter, Kelli J, Marshik, Patricia L, Bickel, Ellen S, Marquez, Jessica L, Yao, Michael V   +4 more
core   +1 more source

Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015

Indian Journal of Endocrinology and Metabolism, 2015
As injectable therapies such as human insulin, insulin analogs, and glucagon-like peptide-1 receptor agonists are used to manage diabetes, correct injection technique is vital for the achievement of glycemic control.
Nikhil Tandon, Sanjay Kalra, Yatan Pal Singh Balhara, Manash P Baruah, Manoj Chadha, Hemraj B Chandalia, Subhankar Chowdhury, Kesavadev Jothydev, Prasanna K. M. Kumar, Madhu S V, Ambrish Mithal, Sonal Modi, Shailesh Pitale, Rakesh Sahay, Rishi Shukla, Annamalai Sundaram, Ambika G Unnikrishnan, Subhash K Wangnoo   +17 more
doaj   +1 more source

Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang, Kevin Cho, Max C. Petersen, Kai E. Jones, Gary J. Patti, Janet B. McGill, Samantha A. DiGruccio   +6 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. [PDF]

PLoS ONE, 2011
BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion.
Chia-Hsuin Chang, Sengwee Toh, Jou-Wei Lin, Shu-Ting Chen, Chuei-Wen Kuo, Lee-Ming Chuang, Mei-Shu Lai   +6 more
doaj   +1 more source

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.

PLoS ONE, 2021
Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years.
Parag Goyal, Harish Venkatraman Pai, Phanichand Kodali, Bhavesh Vats, Navratna Vajpai, Shankara Annegowda, Krishnappa Mane, Shamini Mohan, Shruti Saxena, Anil Bangalore Veerabhadraia, Milee Palande, Preethy Sasankan Nair, Digvijay Chandrashekar More, Umamaheshwara Rao Karudumpa, Kunala Jyothirmai, Adroha Bhattacharya, Frida Almeida, Santosh Gulab Khyade, Shankara Gouda, Daniel J Ranayhossaini, Praveen Reddy Moole, Jeffrey P Smith, Abhijit Barve, Ramakrishnan Melarkode, Rajesh Ullanat   +24 more
doaj   +1 more source

Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang, Zhanru Liu, Shifeng Wang, Cuiyan Lv, Hesham R. El‐Seedi, Shaden A. M. Khalifa, Haiyan Wang   +6 more
wiley   +1 more source

Insulin glargine in enteric tube feeding.

, 2007
Diabetes Res Clin Pract. 2007 Nov;78(2):298-9. Epub 2007 May 3. Insulin glargine in enteric tube feeding. Marchetti G, Tesauro M, Di Daniele N, Bollea MR, Lauro R, Bertoli A.
Bollea, MR, Bertoli, A, BOLLEA, MARIA ROSA, Di Daniele, N, Lauro, R, BERTOLI, ALDO, Marchetti, G, Tesauro, M, LAURO, RENATO, DI DANIELE, NICOLA, TESAURO, MANFREDI   +10 more
core   +1 more source